The role of immune mechanisms in the development and control of prostatic carcinoma appears to be complicated by the endocrine response of some tumors. The progression of endocrine-independent tumors is more directly related to host-immune response. Evaluation of the role of chemotherapeutic agents must include their effect on the host-immune response. The use of BCC in patients with metastatic prostatic carcinoma produces no alteration in cell-mediated immunity but produces local tumor necrosis. The use of nonspecific antigens to enhance host-immune response may be more effective when used as adjuvant therapy in earlier stages of prostatic adenocarcinoma.
Klugo, Richard C.
"Immunologic Assessment in Patients with Prostatic Carcinoma,"
Henry Ford Hospital Medical Journal
: Vol. 23
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol23/iss4/6